Transaction overview
Jazz Pharmaceuticals (US), a pharmaceutical company specializing in rare diseases and oncology, acquired Alizé Pharma II (FR) for up to $20 million on May 11, 2016. The deal primarily secures the rights to Asparec® (pegcrisantaspase), a pegylated recombinant L-asparaginase from Erwinia chrysanthemi, intended for treating acute lymphoblastic leukemia in patients who are hypersensitive to Escherichia coli–derived L-asparaginase. Alizé Pharma II, founded in 2008, is a privately held biopharmaceutical company developing treatments for metabolic diseases and cancer.
Deal structure and financing
The acquisition was structured with an upfront payment of €8 million ($9.1 million) and up to €10 million ($11.4 million) contingent on regulatory milestones being met. The financial details, including the equity and debt split, as well as lead banks involved in the transaction, are not publicly disclosed. No specific leverage metrics or lock-up terms were announced; however, there is no mention of any seller retained stake. Given the deal size, Jazz Pharmaceuticals likely funded this acquisition through its existing cash reserves or a mix of debt and equity financing.
Strategic context
Jazz Pharmaceuticals' rationale for acquiring Alizé Pharma II centers on enhancing its pipeline with Asparec®, an innovative treatment option for acute lymphoblastic leukemia that addresses patient hypersensitivity issues. The acquisition supports Jazz's strategic focus on rare diseases and cancer treatments, aligning with their broader goal of developing therapies with significant unmet medical needs. For Alizé Pharma II, the transaction represents a successful exit strategy, allowing them to divest their lead asset while maintaining sustainability for future drug development projects.
Regulatory path
The regulatory review process was likely limited due to the private nature of the deal and its relatively modest size. Given that the transaction involves cross-border activity between the United States and France, both jurisdictions would need to consider applicable competition laws. However, no specific remedies were required or publicly disclosed by either side. The lack of public information on regulatory filings suggests a straightforward process without significant antitrust concerns.
Jazz Pharmaceuticals was able to integrate Alizé Pharma II's asset into its existing portfolio seamlessly, leveraging the FDA’s Fast-Track designation and orphan drug designations for Asparec® in both the US and Europe. This strategic move positions Jazz Pharmaceuticals to potentially address an important gap in current treatment options for patients with acute lymphoblastic leukemia who suffer from hypersensitivity reactions to standard therapies.